NewCardio(OTC) NWCI

NewCardio, Inc. is a company focused on cardiac diagnostics and related services. The primary goal is to develop innovative software technologies for non-invasive diagnosis and continuous monitoring of cardiovascular diseases.

Products and Services

• QTinno: Automated cardiac safety solution using advanced algorithms
• CardioBip: Mobile ECG system for remote data transmission
• my3KG: Software for comprehensive evaluation of cardiac electrical activity

Growth Outlook

• Increasing demand for non-invasive cardiac diagnostics in healthcare
• Expansion of product offerings to address diverse cardiovascular needs
• Potential partnerships with pharmaceutical companies for drug safety assessments

Financial Highlights

• Recent quarterly revenue of 9,883, reflecting ongoing operational challenges
• Trailing twelve months (TTM) net income margin of -44.66%, indicating significant losses
• Current ratio of 0.72, suggesting liquidity concerns in meeting short-term obligations

NewCardio, Inc. operates in the medical devices sector, specializing in advanced cardiac diagnostic solutions. The company has developed several innovative products aimed at improving the accuracy and efficiency of cardiovascular disease diagnosis and monitoring. Despite facing financial challenges, including negative net income margins and liquidity issues, the company is positioned to capitalize on the growing demand for non-invasive cardiac diagnostics. The potential for partnerships with pharmaceutical companies could further enhance growth prospects, making NewCardio an intriguing option for investors interested in the healthcare technology space.